Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4504253 | 1.00 | EGLN1 (0.45) | EGLN1HIF1A | |
| SCHEMBL4516552 | 0.92 | P4HB (0.37) | EGLN1HIF1A | |
| SCHEMBL4516547 | 0.92 | P4HB (0.37) | EGLN1HIF1A | |
| SCHEMBL4510487 | 0.88 | KDM4E (0.39) | — | |
| SCHEMBL4510491 | 0.88 | KDM4E (0.39) | — | |
| SCHEMBL4520585 | 0.83 | NQO1 (0.42) | — | |
| SCHEMBL4520592 | 0.83 | NQO1 (0.42) | — | |
| SCHEMBL13818111 | 0.83 | EGLN1 (0.45) | EGLN1HIF1A | |
| SCHEMBL2576889 | 0.81 | EGLN1 (0.59) | EGLN1HIF1A | |
| SCHEMBL2284349 | 0.79 | NPC1 (0.42) | EGLN1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143368-A1 | Use of Cinnamoyl Compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-1857104-A1 | USE OF CINNAMOYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143368-A1 | Use of Cinnamoyl Compound | COL2A1, COL1A1, SMAD2 | EGLN1 208/4885HIF1A 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.